-
Clinical Trials & Development2 weeks agoAntifibrotic Drug Pirfenidone Cuts Lung Injury Risk in Immunotherapy-Treated Lung Cancer Patients
A phase II trial found that prophylactic pirfenidone significantly reduced grade 2 or higher radiation-induced lung injury in lung cancer patients previously treated with immune checkpoint...
-
Clinical Trials & Development2 weeks agoAstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated...
-
Clinical Trials & Development2 weeks agoVanda freezes Novartis-originated social anxiety program after late-stage disappointment
While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for...
-
Clinical Trials & Development2 weeks agoQCi and INmune Bio partner to study XPro in Alzheimer’s
The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will...
-
Clinical Trials & Development2 weeks agoAlentis and PinotBio partner to develop claudin-1 oncology ADCs
Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive...
-
Clinical Trials & Development2 weeks agoAlzheimer’s Small-Molecule Therapy Shows Promise in Mice and Early Human Trial
A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies for Alzheimer's disease and was well tolerated in a Phase I trial....
-
Clinical Trials & Development2 weeks agoBlood Sugar Spike Plus Frailty Flags Fivefold Death Risk in Heart Patients
A study of 5,580 ICU patients with coronary heart disease shows that combining the stress hyperglycemia ratio with a laboratory-based frailty index identifies a subgroup facing...
-
Clinical Trials & Development2 weeks agoJ&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase...
-
Clinical Trials & Development2 weeks agoBeyond patient matching: AI’s role in reshaping trial recruitment
BIOCENTURY | PRODUCT DEVELOPMENTBEYOND PATIENT MATCHING: AI’S ROLE IN RESHAPING TRIAL RECRUITMENTTriNetX, Paradigm, and Tempus tackle feasibility, enrollment workflows, and site activation through different models
-
Clinical Trials & Development2 weeks agoBioNTech sticks with cancer vaccine despite trial miss
BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
